Standout Papers

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With... 2023 2026 202474
  1. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes (2023)
    Aditi R. Saxena, Juan P. Frías et al. JAMA Network Open

Immediate Impact

1 by Nobel laureates 8 from Science/Nature 64 standout
Sub-graph 1 of 22

Citing Papers

Mapping the effectiveness and risks of GLP-1 receptor agonists
2025 Standout
Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis
2025 Standout
2 intermediate papers

Works of Lisa Brown being referenced

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
2023 Standout
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
2017

Author Peers

Author Last Decade Papers Cites
Lisa Brown 170 92 111 113 25 653
Chongqi Jia 120 74 114 65 33 627
Shahnaz Khan 89 102 57 94 29 760
G. Berglund 176 90 140 109 16 785
Jagoda Jorga 114 180 151 143 36 667
Kathleen Daniels 97 76 164 80 23 801
Yang Xu 169 72 82 43 34 630
Rebecca Harvey 94 219 134 75 19 731
Phillip Tuso 124 65 139 50 21 762
Yeonhee Lee 78 114 83 94 34 590
R Pascone 165 256 70 253 30 777

All Works

Loading papers...

Rankless by CCL
2026